{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T19:25:41Z","timestamp":1763580341706,"version":"3.44.0"},"reference-count":29,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,8,21]]},"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:p>Dipeptidyl peptidase 4 (DPP-4) inhibitors are increasingly used these days in management of diabetes. There has been reported in a few case reports of increasing association between DPP-4 inhibitor use and bullous pemphigoid (BP). We report a case of association between linagliptin use and BP and subsequent treatment with rituximab.<\/jats:p>","DOI":"10.1136\/bcr-2019-229902","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T16:24:49Z","timestamp":1569860689000},"page":"e229902","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Linagliptin-associated bullous pemphigoid treated with rituximab"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4591-7202","authenticated-orcid":false,"given":"Hariharasudan","family":"Mani","sequence":"first","affiliation":[{"name":"Internal Medicine, Marshfield Clinic, Eau Claire, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Safo","sequence":"additional","affiliation":[{"name":"Ascension Health Care, Dermatology, Stevens Point, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adedayo A","family":"Onitilo","sequence":"additional","affiliation":[{"name":"Oncology, Marshfield Clinic Weston Center, Weston, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,9,30]]},"reference":[{"key":"2025082708395674000_12.9.e229902.1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.det.2011.03.010","article-title":"Clinical features and practical diagnosis of bullous pemphigoid","volume":"29","author":"Schmidt","year":"2011","journal-title":"Dermatol Clin"},{"key":"2025082708395674000_12.9.e229902.2","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2011.606447"},{"key":"2025082708395674000_12.9.e229902.3","first-page":"461","volume-title":"Dermatology","volume":"1","author":"Pemphigus","year":"2012"},{"key":"2025082708395674000_12.9.e229902.4","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.301"},{"key":"2025082708395674000_12.9.e229902.5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.16.8569"},{"key":"2025082708395674000_12.9.e229902.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.04.003"},{"key":"2025082708395674000_12.9.e229902.7","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bjd.15195","article-title":"The association between drugs and bullous pemphigoid","volume":"176","author":"Tan","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025082708395674000_12.9.e229902.8","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2025082708395674000_12.9.e229902.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01610.x"},{"key":"2025082708395674000_12.9.e229902.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k872"},{"key":"2025082708395674000_12.9.e229902.11","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0482"},{"key":"2025082708395674000_12.9.e229902.12","unstructured":"U.S. National Library of medicine. DailyMed. Available at http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?id=87103."},{"key":"2025082708395674000_12.9.e229902.13","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/pds.3503","article-title":"Association of musculoskeletal complaints and gliptin use: review of spontaneous reports","volume":"22","author":"Tarapu\u00e9s","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025082708395674000_12.9.e229902.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09300.x"},{"key":"2025082708395674000_12.9.e229902.15","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/ijd.14005","article-title":"Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization","volume":"57","author":"Garc\u00eda-D\u00edez","year":"2018","journal-title":"Int J Dermatol"},{"key":"2025082708395674000_12.9.e229902.16","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3389\/fimmu.2018.01030","article-title":"Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients","volume":"9","author":"Gaudin","year":"2018","journal-title":"Front Immunol"},{"key":"2025082708395674000_12.9.e229902.17","doi-asserted-by":"crossref","unstructured":"Kawaguchi Y , Shimauchi R , Nishibori N , et al . Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients. J Diabetes Investig 2019;10.doi:10.1111\/jdi.12877","DOI":"10.1111\/jdi.12877"},{"key":"2025082708395674000_12.9.e229902.18","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0210"},{"key":"2025082708395674000_12.9.e229902.19","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/ijd.13705","article-title":"Linagliptin-induced bullous pemphigoid","volume":"56","author":"Esposito","year":"2017","journal-title":"Int J Dermatol"},{"key":"2025082708395674000_12.9.e229902.20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/jdi.12695","article-title":"Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases","volume":"9","author":"Yoshiji","year":"2018","journal-title":"J Diabetes Investig"},{"key":"2025082708395674000_12.9.e229902.21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjd.15111","article-title":"Linagliptin-associated bullous pemphigoid that was most likely caused by IgG autoantibodies against the midportion of BP180","volume":"176","author":"Sakai","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025082708395674000_12.9.e229902.22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000443330","article-title":"Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin","volume":"232","author":"Mendon\u00e7a","year":"2016","journal-title":"Dermatology"},{"key":"2025082708395674000_12.9.e229902.23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamadermatol.2015.2939","article-title":"Bullous Pemphigoid Associated With Linagliptin Treatment","volume":"152","author":"Haber","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2025082708395674000_12.9.e229902.24","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jaad.2013.07.009","article-title":"Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180\u00a0and 230 enzyme-linked immunosorbent assays for\u00a0diagnosis of bullous pemphigoid","volume":"69","author":"S\u00e1rdy","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2025082708395674000_12.9.e229902.25","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2011.606447"},{"key":"2025082708395674000_12.9.e229902.26","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.2.174"},{"key":"2025082708395674000_12.9.e229902.27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.2.1120"},{"key":"2025082708395674000_12.9.e229902.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-013-0783-4"},{"key":"2025082708395674000_12.9.e229902.29","doi-asserted-by":"publisher","DOI":"10.2741\/2785"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-229902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:40:04Z","timestamp":1756309204000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-229902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,30]]},"published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1136\/bcr-2019-229902"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-229902","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}